Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Study reveals mechanism of action of laquinimod in patients with RRMS

Laquinimod is an orally available synthetic compound that has been successfully evaluated in phase II/III clinical studies for the treatment of relapsing-remitting multiple sclerosis (RRMS).

6 Dec 2011

Biogen, Samsung partner to develop and market biosimilars

Samsung and Biogen Idec today announced that they have entered into an agreement to invest $300 million to establish a joint venture to develop, manufacture and market biosimilars. Samsung will take a leading role in the joint venture, with Biogen Idec contributing its expertise in protein engineering and biologics manufacturing.

5 Dec 2011

Researchers identify critical steps leading to myelin destruction in neuromyelitis optica

Mayo Clinic researchers have identified critical steps leading to myelin destruction in neuromyelitis optica (NMO), a debilitating neurological disease that is commonly misdiagnosed as multiple sclerosis (MS). The findings could lead to better care for the thousands of patients around the world with NMO. The paper was published in the journal, Proceedings of the National Academy of Sciences, USA.

3 Dec 2011

Positive interim data from Anthera's PEARL-SC phase 2b clinical study in systemic lupus erythematosus

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced positive interim biomarker data from the PEARL-SC phase 2b clinical study in patients with systemic lupus erythematosus.

1 Dec 2011

Compugen's Antibody Target Discovery Platform presented at 7th Annual European Antibody Congress

Speaking today at the plenary session of the 7th Annual European Antibody Congress in Geneva, Dr. Anat Cohen-Dayag, President and CEO of Compugen Ltd., presented Compugen's Antibody Target Discovery Platform, one of the Company's predictive discovery platforms for novel therapeutic targets.

1 Dec 2011

Immune system stimulant used as suppressor to treat chronic graft-versus-host disease

In a study that seems to pivot on a paradox, scientists at Dana-Farber Cancer Institute have used an immune system stimulant as an immune system suppressor to treat a common, often debilitating side effect of donor stem cell transplantation in cancer patients. The effect, in some cases, was profound.

1 Dec 2011

IOMSN, AANN and ARN publish Nursing Management of the Patient with Multiple Sclerosis guideline

The American Association of Neuroscience Nurses (AANN), the Association for Rehabilitation Nurses (ARN) and the International Organization of Multiple Sclerosis Nurses (IOMSN) are proud to announce the newest addition to the respected AANN Clinical Practice Guideline series, Nursing Management of the Patient with Multiple Sclerosis.

1 Dec 2011

New marker may provide more accurate diagnosis of Alzheimer's, FTLD

New research finds a marker used to detect plaque in the brain may help doctors make a more accurate diagnosis between two common types of dementia - Alzheimer's disease and frontotemporal lobar degeneration.

1 Dec 2011

First study to investigate risk factors for CCSVI in patients without neurological disease

The first study to investigate risk factors for the vascular condition called CCSVI (chronic cerebrospinal venous insufficiency) in volunteers without neurological disease has identified what the researchers call a remarkable similarity between this condition and possible or confirmed risk factors for multiple sclerosis.

1 Dec 2011

Neuropharmacology to publish Nutra Pharma's Alpha-Cobratoxin mechanism study on chronic pain

Nutra Pharma Corporation, a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the journal Neuropharmacology will be publishing a mechanism study on the use of Alpha-Cobratoxin, a component of cobra venom, as a treatment for pain.

1 Dec 2011

ACGME approves Cedars-Sinai's neurology residency training program

The Accreditation Council for Graduate Medical Education has approved a neurology residency training program at Cedars-Sinai Medical Center. Recruitment of the first group of three residents is under way through the 2012 "match," a process in which an independent organization pairs applicants with programs to meet the preferences of each.

30 Nov 2011

Kessler Foundation scientists to investigate cognitive reserve in TBI

Denise Krch, PhD, and James Sumowski, PhD, research scientists in the Neuropsychology and Neuroscience Laboratory at Kessler Foundation, received a $379,000 grant for a three-year study of cognitive reserve in people with traumatic brain injury.

30 Nov 2011

Counterparts of memory cells ward off microbial foes

The immune system possesses a type of cell that can be activated by tissues within the body to remind the immune system not to attack our own molecules, cells and organs, UCSF researchers have discovered.

29 Nov 2011

Improving patient adherence to medications for chronic diseases can reduce overall treatment costs

Avi Dor, Ph.D., professor in the Department of Health Policy, GW School of Public Health and Health Services, was a co-author of a study, in collaboration with Teva Pharmaceuticals, that found that higher patient adherence to disease modifying therapies, like glatiramer acetate (GA), an immunomodulator drug currently used to treat multiple sclerosis, reduced inpatient costs, outpatient costs, and other medical expenses in a national sample of multiple sclerosis patients.

29 Nov 2011

PAREXEL implements fMRI technology in early phase CNS drug development

PAREXEL International, a leading global biopharmaceutical services provider, today announced that it has enhanced its central nervous system (CNS) capabilities for clinical development through the implementation of functional magnetic resonance imaging (fMRI) technology in its Early Phase units.

From Parexel 22 Nov 2011

Study examines link between early-stage Alzheimer's and lower BMI

Studies have shown that people who are overweight in middle age are more likely to develop Alzheimer's disease decades later than people at normal weight, yet researchers have also found that people in the earliest stages of Alzheimer's disease are more likely to have a lower body mass index (BMI). A current study examines this relationship between Alzheimer's disease and BMI.

22 Nov 2011

Adeona to develop and commercialize DNA-based therapeutic for PAH using Intrexon technology

Adeona Pharmaceuticals, Inc., and the Human Therapeutics Division of Intrexon Corporation, announced today the formation of a global exclusive channel collaboration through which Adeona intends to develop and commercialize a DNA-based therapeutic using Intrexon's UltraVector platform and RheoSwitch Therapeutic System for the treatment of pulmonary arterial hypertension (PAH).

21 Nov 2011

Two RegeneRx cardiac-related patents receive notice of allowance in Australia, Mexico

RegeneRx Biopharmaceuticals, Inc. announced today that the Company has been notified that two cardiac-related patents will be allowed in Australia and Mexico.

18 Nov 2011

Modified story memory technique may help cognitive rehabilitation in MS patients

John DeLuca, PhD, Vice President for Research at Kessler Foundation presented findings on the use of a behavioral technique for cognitive rehabilitation in people with multiple sclerosis (MS).

17 Nov 2011

CF Foundation, Genzyme announce new drug research agreement

Genzyme, a Sanofi company, and Cystic Fibrosis Foundation Therapeutics Inc., the nonprofit affiliate of the Cystic Fibrosis Foundation, today announced a research agreement to support the discovery of new drugs to treat people with the most common mutation found in patients with CF, Delta F508.

17 Nov 2011

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Study reveals mechanism of action of laquinimod in patients with RRMS

Biogen, Samsung partner to develop and market biosimilars

Researchers identify critical steps leading to myelin destruction in neuromyelitis optica

Positive interim data from Anthera's PEARL-SC phase 2b clinical study in systemic lupus erythematosus

Compugen's Antibody Target Discovery Platform presented at 7th Annual European Antibody Congress

Immune system stimulant used as suppressor to treat chronic graft-versus-host disease

IOMSN, AANN and ARN publish Nursing Management of the Patient with Multiple Sclerosis guideline

New marker may provide more accurate diagnosis of Alzheimer's, FTLD

First study to investigate risk factors for CCSVI in patients without neurological disease

Neuropharmacology to publish Nutra Pharma's Alpha-Cobratoxin mechanism study on chronic pain

ACGME approves Cedars-Sinai's neurology residency training program

Kessler Foundation scientists to investigate cognitive reserve in TBI

Counterparts of memory cells ward off microbial foes

Improving patient adherence to medications for chronic diseases can reduce overall treatment costs

PAREXEL implements fMRI technology in early phase CNS drug development

Study examines link between early-stage Alzheimer's and lower BMI

Adeona to develop and commercialize DNA-based therapeutic for PAH using Intrexon technology

Two RegeneRx cardiac-related patents receive notice of allowance in Australia, Mexico

Modified story memory technique may help cognitive rehabilitation in MS patients

CF Foundation, Genzyme announce new drug research agreement

Industry Focus: Cell & Gene Therapy eBook

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Unlocking live single-cell functional insights

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Industry Focus: Cell & Gene Therapy eBook

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Unlocking live single-cell functional insights

Newsletters you may be interested in